A Phase 1 interventional study of [14C]-CTP-543 in Healthy Volunteers, sponsored by Concert Pharmaceuticals. Completed at 1 site in United States. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-25.
Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess the absorption, metabolism, excretion, mass balance, safety, and tolerability of a single oral administration of [14C]-CTP-543 in healthy male subjects.
Concert Pharmaceuticals is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.
First submitted before Concert Pharmaceuticals became part of Sun Pharmaceutical Industries Limited.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
\[14C\]-CTP-543
Drug: [14C]-CTP-543
Single dose of radiolabeled CTP-543 (approximately 75 μCi) administered as an oral solution
Mass balance: Calculation of percent of total radioactivity recovered in urine
Time frame: From time zero up to 96 hours post-dose following oral administration of [14C]-CTP-543 up to Day 15
Mass balance: Calculation of percent of total radioactivity recovered in feces
Time frame: From time zero up to 96 hours post-dose following oral administration of [14C]-CTP-543 up to Day 15
CTP-543 PK: Cmax
Maximum plasma concentration
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose
CTP-543 PK: Tmax
Time for Cmax
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose
CTP-543 PK: t1/2
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose
CTP-543 PK: AUClast
Area under the plasma concentration time profile from time 0 to time of the last quantifiable concentration (Clast)
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose
CTP-543 PK: AUCinf
Area under the plasma concentration time profile from time 0 to infinity
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose
CTP-543 PK: CL/F
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes).
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose
CTP-543 PK: Vz/F
Apparent volume of distribution following oral administration
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose
CTP-543 metabolite PK: Cmax
Maximum plasma concentration
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose
CTP-543 metabolite PK: Tmax
Time for Cmax
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose
CTP-543 metabolite PK: t1/2
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose
CTP-543 metabolite PK: AUC0-last
Area under the plasma concentration time profile from time 0 to time of the last quantifiable concentration (Clast)
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose
CTP-543 metabolite PK: AUCinf
Area under the plasma concentration time profile from time 0 to infinity
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose
Total [14C]: urine
Total radioactivity excreted into the urine from time zero to the time of last measurable concentration following oral administration of \[14C\]-CTP-543
Time frame: Pre-dose up to 336 hours post-dose
Total [14C]: feces
Total radioactivity excreted into the feces from time zero to the time of last measurable concentration following oral administration of \[14C\]-CTP-543
Time frame: Pre-dose up to 336 hours post-dose
Total radioactivity in whole blood
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose
Total radioactivity in plasma
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose
Adverse events
Number of adverse events, which are any untoward medical occurrence regardless of attribution to study drug in a participant who received study drug
Time frame: Screening up to Day 15
Number of Participants With Clinically Significant Change From Baseline in Heart Rate
Heart rate measured in beats per minute (bpm)
Time frame: Screening, Pre-dose, 2, 8, 48 hours post-dose
Number of Participants With Clinically Significant Change From Baseline in Blood Pressure
Blood pressure measured in millimeters of mercury (mmHg)
Time frame: Screening, Pre-dose, 2, 8, 48 hours post-dose
Number of Participants With Clinically Significant Change From Baseline in Respiratory Rate
Respiratory rate measured in breaths per minute
Time frame: Screening, Pre-dose, 2, 8, 48 hours post-dose
Number of Participants With Clinically Significant Change From Baseline in Temperature
Temperature measured in Celsius (°C)
Time frame: Screening, Pre-dose, 2, 8, 48 hours post-dose
Number of Participants With Clinically Significant Change From Baseline in Hematology
Time frame: Screening, Check-in, 8, 24 hours postdose
Number of Participants With Clinically Significant Change From Baseline in Serum Chemistry
Time frame: Screening, Check-in, 8, 24 hours postdose
Number of Participants With Clinically Significant Change From Baseline in Coagulation
Time frame: Screening, Check-in, 8, 24 hours postdose
Number of Participants With Clinically Significant Change From Baseline in Urinalysis
Time frame: Screening, Check-in, 8, 24 hours postdose
Number of Participants With Clinically Significant Changes to the Physical Examination
Clinically significant changes to the physical examination
Time frame: Screening up to Day 15
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram - P Wave
Time frame: Screening, Pre-dose, 48 hours post-dose
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram - QRS Complex
Time frame: Screening, Pre-dose, 48 hours post-dose
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram - QT Interval
Time frame: Screening, Pre-dose, 48 hours post-dose
Ran from Sep 2019 to primary completion in Sep 2019, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deuruxolitinib